Anorexia Nervosa
Conditions
Interventions
None listed
Sponsors
Universiteit Utrecht
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: BODY SCHEMA STUDY Patients Female, between 18 and 35 years of age, diagnosed with Anorexia Nervosa, physically non-disabled (i.e. able to perform tasks involving walking, and placing objects in boxes). Healthy controls Female, between 18 and 35 years of age, BMI between 19 and 25, no current severe mental health problems, physically non-disabled (i.e. able to perform tasks involving walking, and placing objects in boxes).;PMT PILOT Patients Female, over 18 years of age, diagnosed with AN, participating in the PMT group as part of treatment Healthy controls Female, over 18 years of age, not diagnosed with AN
Exclusion criteria
Exclusion criteria: BODY SCHEMA Patients Use of medication that may influence task performance due to sedative effects, drowsiness or (psycho)motor impairments, comorbid Borderline personality disorder or contact disorder, recent start of treatment, treatment in the day-group, pregnancy. Healthy controls Use of medication that may influence task performance due to sedative effects, drowsiness or (psycho)motor impairments, pregnancy.;PMT PILOT No specific exclusion criteria, unrelated to not fulfilling the inclusion criteria. Ofcourse, if the therapist has any reason to advise against participation of the AN patients in the pilot, we will not include this patient in our sample.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| BODY SCHEMA The Body Schema task will be used to assess possible disturbances in body schema. De outcome measure of this task is the A/S (aperture to shoulder ratio), which is based on the smallest aperture for which participants rotate their shoulders when they walk through it, and the participants* shoulder width. It will be tested whether AN patients and controls have different A/S values. PMT PILOT The PMT pilot contains one main study variable, namely changes in body schema over time (pre vs post assessment). Body schema is assessed with an imagery task in which participants judge whether they would fit through hoops varying in size, while imagining performing this action. We will calculate the critical hoop ratio, based on the smallest hoop for which participants indicated they would fit through at least two out of three trials. | — |
Secondary
| Measure | Time frame |
|---|---|
| BODY SCHEMA In order to investigate the first secondary objective of the first study, body dissatisfaction will be assessed with two questionnaires: The Body Shape Questionnaire en de Physical Appearance State and Trait Anxiety Scale: Sate. The outcome measures for body dissatisfaction is the sum score of both questionnaires. It will be tested whether body dissatisfaction measures correlate with A/S values. In order to investigate the second secondary objective of the current study body image will be assessed by asking participants to estimate their shoulder width. This size estimation will be used to determine the outcome measure A/S* (aperture to estimated shoulder size ratio). It will be tested whether AN patients and controls have different A/S* values. PMT PILOT The PMT pilot has three secundary study variables. First, to investigate whether the body-schema directed intervention affects body attitudes, it will be tested whether differences in pre- and post-assessment on Body Shape Questionnaire scores (sum score). Second, to investigate whether the body-schema directed intervention visual body image, it will be tested whether differences in pre- and post-assessment of visual body image can be identified. Visual body image will be assessed by asking participants to draw a line representing their shoulder and hip width. Third, to investigate whether the body-schema directed intervention affects tactile body image, it will be tested whether differences in pre- and post-assessment of tactile body image can be identified. Tactile body image will be assessed with the Tactile Estimation Task, of which the outcome measure is the mean distance estimation over all trials. | — |
Countries
Netherlands
Outcome results
None listed